Colorectal cancer (CRC) is one of the leading causes of mortality in the western world. It is widely accepted that neoplasms such as colonic polyps are precursors to CRC formation; with the polyp-adenoma-carcinoma sequences well described in medical literature.[1,2] It has been shown that Aspirin and other non-steroid anti-inflammatory drugs (NSAID) have a negative effect on polyp and cancer formation. This review aims to describe some of the mechanism behind the chemoprotective properties of aspirin; COX 2 inhibition, regulation of proliferation and apoptosis and effects on the immune system and also the current evidence that supports its use as a chemoprevention agent against CRC. We will also aim to explore the side effects with the use of aspirin and the pitfalls of using aspirin routinely for primary prophylaxis against CRC.
Introduction
Important insights gained among these observational studies include the facts that the chemopreventive effect is probably dose dependent; that benefit is only observed after an extended duration of using aspirin and that the effect is nullified on cessation of the drug for at least one year. [80, 82, 83, 86] Controversies remain regarding the minimum dose of aspirin required to see a chemopreventive effect. A case control study involving 5,186 patients showed that even the lowest dose of aspirin (75mg) conferred a protective effect against CRC evident after 1 year and increasing with duration use. [73] There is however conflicting evidence that suggests that doses below 300mg are unhelpful.
[82] On foot of these findings randomised controlled trials were developed to further assess the relationship between aspirin and CRC. The first published randomised controlled trial came from the physicians health study (PHS) involving 22,071 male physicians. At a dose of 325mg of Aspirin every other day the study did not detect an association with reduced risk of colorectal cancer after a median follow up of 5 years. [89] In the Women's Health Study (WHS), a large scale randomised control trial with an average of 10 years follow up; aspirin dose of 100mg on alternate day similarly did not show any benefit in terms of lowering the risk of colorectal cancer. [90] However pooled analysis of two randomised trials; the British Doctors Aspirin Trial (BDAT) and the UK-TIA Aspirin Trial (UK-TIA); were able to demonstrate a significant reduction in the incidence of CRC with aspirin use of 5 years or more [pooled Relative Risk(RR)=0.74, 95% Confidence Interval(CI)=0.56-0.97) though there was a latency period of 10 years before the effect becomes apparent.
[91] It is also interesting to note that the aspirin doses for these two trials were considerably higher than the WHS and PHS. In the BDAT doctors randomised to the treatment arm were taking 500mg of soluble aspirin daily (or 300mg enteric coated) while subjects in the UK-TIA were assigned either 300mg or prescribe an aspirin dose in excess of those associated with cardio protective properties, for a chemopreventive effect, there is also an increasing body of literature to support the efficacy of a lower dose of daily aspirin, which is more likely to be tolerated by patients due to side effects. Long term follow up, 20 years, of four trials of daily low-dose aspirin (75-300mg) in prevention of vascular events showed that with prolonged treatment, more than 5 years there is an absolute reduction in CRC of 1.75% overall. It is of significant interest that this effect is most prominent for proximal colon cancer where a risk reduction of up to 70% was observed with aspirin users. [94] . Table 3 ..
Prevention of CRC in at Risk Groups
There is also an increasing body of evidence to support the use of aspirin in secondary prevention and in patients who are at a higher risk of developing CRC. Baron et al investigated the effect of aspirin on patients with a recent history of colorectal adenomas in the Aspirin/Folate Polyp Prevention Study (AFPPS). In this randomised controlled trial with 1121 subjects, users of low dose aspirin (81mg daily) had a relative risk of 0.81 for adenomas and 0.59 for advanced neoplasms on follow up colonoscopy after 3 years. [95] The subject group taking 325mg of aspirin daily did not have a reduction in adenoma or advanced adenoma risk in this study. The United Kingdom Colorectal Adenoma Prevention Study (UK CAP); a randomised double blinded multi-center trial of aspirin (300mg daily) and folate supplements to prevent colorectal adenoma recurrence, in contrast showed a relative risk reduction of 21% and 37% for adenomas and advanced adenomas respectively when compared to placebo controls after 3 years follow up. [96] The Association pour la Prevention par l'Aspirine du Cancer Colorectal (APACC) study group in France looked at the effect of long term aspirin (160mg and 300mg daily versus placebo) on adenoma recurrence. They reported a protective effect at 1year's follow up but after a follow up of 4 years there was no statistical difference in adenoma recurrence rate between users and non-users of aspirin. This finding, however, has to be interpreted with caution due to a lack of statistical power of the final analysis due to excessive drop patients treated with aspirin 600mg/day for at least a year showed a trend towards reduced polyp numbers in the sigmoid and rectum though it did not reach statistical significance. They did however discover that there was a significant reduction in the size of the largest polyp noted on endoscopy for aspirin users of more than 1 year. [102] Burn et al also conducted a similar trial on a cohort of patients with Lynch syndrome; an autosomal dominant genetic defect in mismatch repair genes predisposing to the development of CRC. This trial in which 693 patients were randomly assigned to using aspirin 600mg daily or placebo failed to detect any difference in the incidence of colorectal adenoma or carcinoma after an average follow up of 29 months. [103] The reason for the seemingly lack of efficacy of aspirin in these two hereditary forms of CRC is unknown but one explanation could be the lesser potency of aspirin against COX-II activity compared to other NSAIDs. Nevertheless this underscores the notion that chemopreventive properties noted in a particular NSAID are not always generalisable to other NSAIDs and further research is needed to advocate the use of aspirin for chemoprevention in the setting of FAP and HNPCC.
Prevention of CRC Recurrence
Tertiary prevention of CRC; that is the prevention of recurrence of CRC or its precursors in a patient with previous history of treated CRC, is also an area that aspirin is seen to be useful. Chan et al conducted a prospective cohort study of 1279 patients who were diagnosed with stage I, II or III CRC. When compared to non users of aspirin post diagnosis with CRC, aspirin users has a reduced risk of CRC related mortality (RR= 0.71) on median follow up of 11.8 years. [104] On further analysing for COX-2 expression in the tumour tissue, aspirin use was only associated with decreased mortality in patients whose primary tumour expressed high levels of COX-2. There was no reduction in risk in aspirin users whose tumour expressed weak or absent levels of COX-2. [104] Interestingly in this study, CRC mortality was not seen to be reduced in patients who used aspirin regularly prior to the diagnosis of CRC nor was a reduction in mortality observed on continuation of aspirin post diagnosis. This is certainly in contrast to the observations found in an extension of the California Teachers Study (CTS) where the authors found a reduction of CRC related mortality with aspirin and NSAIDs use pre diagnosis of CRC [105] but intriguingly this effect was only noted in patients with low meat consumption. [106] Finally, a randomised controlled trial investigated the effect of daily aspirin (325mg) on patients with a history of non-metastatic CRC who had undergone curative resection and reported a significant reduction in the risk of recurrent adenoma in the aspirin group as compared to placebo (RR= 0 vomiting and dyspepsia occur more frequently. Aspirin is also ulcerogenic and is associated with increased risk of upper GI bleeding, potentially precipitating major bleeds requiring transfusion. [109] A meta-analysis of 21 randomised controlled trials comparing aspirin and placebo found an increased risk of GI bleeding with aspirin; pooled odds ratio 1.5 to 2.0. The risk of peptic ulcers and upper GI symptoms were increased at 1.3 and 1.7 respectively. [110] Also importantly this GI side effect seemed to be dose related. [110] While some studies have suggested that low daily doses of aspirin (75mg) are sufficient to confer a chemopreventive benefit; such doses are still associated with increased GI bleeding. [111] Aspirin therapy has also been shown to be associated with increased risk of haemorrhagic stroke due to its anti-platelet effects. A met-analysis of 16 randomised controlled trials with 55,462 participants reported an absolute increase of 12 events per 10,000 persons treated with aspirin. [112] Other aspirin related side effects include renal insufficiency, but this is usually encountered at doses much higher than that used in cardiovascular or for chemopreventive purposes. [109] Aspirin could also worsen the respiratory status in a small percentage of asthmatic patients due to aspirin sensitivity. [113] In light of the current evidence the US Preventive Services Task Force (USPSTF) recommended against the routine use of aspirin for the prevention of CRC in individuals at average risk for CRC as it was felt that the harms outweigh the benefits. [114] All patients older than 50 who are at average risk for CRC should be screened for CRC regardless of their aspirin or NSAID status according to the USPSTF.
Cost Effectiveness and Added Value
Given the work that has been done to show the chemopreventive properties of aspirin, cost effective analyses have been carried out to determine if routine aspirin chemoprevention is a cost effective strategy against the development of CRC. A study based on data from the U.S. population found that adding aspirin (325mg daily) to patients who adhere to CRC screening was not cost effective. They also concluded that aspirin chemoprophylaxis alone cannot be a substitute for CRC screening. [115] Another U.S. study compared the cost effectiveness of chemoprevention with aspirin (325mg daily) against the strategies of no intervention; screening colonoscopy and lastly a combination of both aspirin and colonoscopy strategy in the prevention of CRC. They reported an incremental cost-effectiveness ratio (ICER) of $47,249 per life-year saved for aspirin compared to no intervention while the ICER for colonoscopy was calculated at $10,983 per life-year saved compared to no intervention. This implied screening colonoscopy is a more cost effective measure to prevent CRC than chemoprevention with aspirin. On combining both strategies, the ICER was $227,607 per life-year saved compared with screening colonoscopy alone; suggesting that such a strategy is unlikely to be cost effective when applied to the general U.S. population. [116] While these studies were disappointing it should be noted that economic evaluation based on the U.S healthcare delivery system may not be generalisable to healthcare systems in other countries. Cooper et al conducted a cost effective analysis applicable to the National Health Service in the U.K and found that the use of aspirin as an adjunct to CRC screening was a cost effective strategy when administered to the general population from age 50 to 60 years. [117] Furthermore the use of aspirin in individuals with increased risk of CRC seems per life-year gained. [118] Similar results were also noted on cost effectiveness analysis on patients with intermediate risk for CRC in the NHS setting. [117] It should be noted that the evidence and economic evaluation of aspirin presented thus far only home in on its chemopreventive effect on CRC. Aspirin also has other added benefits that can be of value to the target population. Its anti-platelet properties are known to be effective in the chemoprevention of cardiovascular disease. [19, 109] Aspirin use has also been associated with reduced risk of other cancers, including gastric, endometrial, pancreatic, oesophageal and lung cancer. [119] [120] [121] [122] [123] In fact, a met-analysis of 8 randomized trials involving 25,570 patients looking at the effect of aspirin on cancer deaths demonstrated a reduction in the overall risk of cancer deaths in the aspirin group compared to controls (RR= 0.80, 95%CI=0.72-0.88); with an absolute reduction in 20-year risk of cancer death reaching 7.08% at age 65 and older. This observed protective effect was noted to be greatest for adenocarcinomas (RR= 0.66, 95%CI=0.56-0.77). Importantly, this benefit was only apparent after 5 years of aspirin use and did not appear to increase at aspirin dose greater than 75mg. [124] Finally it could also be useful in augmenting the effectiveness of some modalities of CRC screening. One study found that low dose aspirin enhanced the performance of faecal immunochemical test (FIT) in the detection of CRC and polyps in a screening population by inducing microbleeding in the lesions, thereby increasing the amount of haemoglobin present in the faecal sample. [125] 
Future direction and Conclusion
Despite the fact that it was first developed over 150 years ago, aspirin has continued to remain relevant through the history of medicine. From its first use as an antipyretic and anti-inflammatory agent; it has evolved into an important therapeutic agent both in the treatment and prevention of cardiovascular disease. Now its role in the prevention of cancer; the leading cause of death worldwide, is being explored. While there are encouraging results to support aspirin as a chemoprevention drug in CRC; conflicting data from clinical trials mandate that further research will be needed prior to prescribing this medication to the general population solely for this indication. It is likely that further research will concentrate on selecting out the population that would benefit most from such intervention. In particular, those in whom aspirin imparts the most risk reduction in CRC incidence and mortality while avoiding complications associated with its usage in the long term. Although aspirin chemoprophylaxis cannot be recommended for use in the general population, in certain at risk groups in particular patients with a history of CRC or advanced adenomas its use could be considered on a case by case basis.
Further research into the development of novel compounds with better efficacy and safety profile is also in progress. [126] One such compound; Nitric oxide-donating aspirin (NO-ASA), is currently being investigated for its efficacy in inhibiting tumourigenesis. [127, 128] .
In conclusion, the discovery of aspirin and the prostaglandin synthesis pathway have led to enhanced understanding of CRC pathogenesis. Future work into factors influencing this pathway and its interaction with tumour biology will certainly add towards the armamentarium against the occurrence, and not least the recurrence of this common but deadly disease. 
